% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

  • buffet_partner buffet_partner Aug 30, 2012 3:18 AM Flag

    Fellow investors: Research Sarepta(SRPT) ASAP

    Sarepta(SRPT) is biopharma developing a treatment for Duchenne Muscular Dystrophy disease. The company reported impressive interim results. Granted the study has a small patient population, however, the results are quite impressive nevertheless. The stock appreciated very significantly since the reporting the results. However, it is in my opinion that more appreciation potential still exists.